MXPA03000316A - Reactivos y metodos para la identificacion de agentes de enlace. - Google Patents

Reactivos y metodos para la identificacion de agentes de enlace.

Info

Publication number
MXPA03000316A
MXPA03000316A MXPA03000316A MXPA03000316A MXPA03000316A MX PA03000316 A MXPA03000316 A MX PA03000316A MX PA03000316 A MXPA03000316 A MX PA03000316A MX PA03000316 A MXPA03000316 A MX PA03000316A MX PA03000316 A MXPA03000316 A MX PA03000316A
Authority
MX
Mexico
Prior art keywords
protein
binding
threonine
polypeptide
peptide
Prior art date
Application number
MXPA03000316A
Other languages
English (en)
Inventor
Peter Davies
Original Assignee
Molecular Geriatrics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Geriatrics Corp filed Critical Molecular Geriatrics Corp
Publication of MXPA03000316A publication Critical patent/MXPA03000316A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se describe un metodo para identificar un agente de enlace deseado que interfiere con la interaccion entre una proteina, fragmento de proteina, polipeptido o un peptido y un sustituto de enlace. El metodo comprende la combinacion de la proteina, el fragmento de proteina, el polipeptido o el peptido, el sustituto de enlace y un agente de enlace. La deteccion de una disminucion en la interaccion entre la proteina, el fragmento de proteina, el polipeptido o peptido a partir del sustituto de enlace, detecta que el agente de enlace interfiere con la interaccion. Las proteinas utiles en el metodo incluyen la proteina tau fosforilada en la treonina (231), la Proteina Precursora Amiloide (APP) fosforilada en la treonina (668), y cdc25 fosforilada en la treonina (48). Los compuestos identificados mediante el metodo son utiles en el tratamiento de la enfermedad de Alzheimer y el cancer.
MXPA03000316A 2000-07-11 2001-07-11 Reactivos y metodos para la identificacion de agentes de enlace. MXPA03000316A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21760400P 2000-07-11 2000-07-11
PCT/US2001/021859 WO2002004949A2 (en) 2000-07-11 2001-07-11 Reagents and methods for identification of binding agents

Publications (1)

Publication Number Publication Date
MXPA03000316A true MXPA03000316A (es) 2004-04-05

Family

ID=22811750

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03000316A MXPA03000316A (es) 2000-07-11 2001-07-11 Reactivos y metodos para la identificacion de agentes de enlace.

Country Status (7)

Country Link
US (1) US20050221391A1 (es)
EP (1) EP1301531A2 (es)
JP (1) JP2004503747A (es)
AU (1) AU2001273361A1 (es)
CA (1) CA2415919A1 (es)
MX (1) MXPA03000316A (es)
WO (1) WO2002004949A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799526B2 (en) 2002-11-21 2010-09-21 The University Of North Carolina At Chapel Hill Phosphoprotein detection reagent and methods of making and using the same
WO2004096199A2 (en) * 2003-05-02 2004-11-11 Scottish Biomedical Limited Regulation of guanine nucleotide exchange factor
WO2007068105A1 (en) * 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
SI2408807T1 (sl) * 2009-03-18 2021-11-30 Ac Immune Sa Postopek za terapevtsko uporabo
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
US8771693B2 (en) 2009-10-27 2014-07-08 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
MY164376A (en) 2010-10-07 2017-12-15 Univ Leuven Kath Phosphospecific antibodies recognizing tau
AU2013205313B2 (en) * 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
US10487114B2 (en) * 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
AR092779A1 (es) 2011-10-07 2015-05-06 Ac Immune Sa Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau
CA2869438C (en) 2012-04-05 2021-08-17 Ac Immune S.A. Humanized tau antibody
BR112015003326A2 (pt) 2012-08-16 2017-07-04 Ipierian Inc métodos de tratamento de uma tauopatia
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
JP6568514B2 (ja) 2013-03-15 2019-08-28 エーシー イミューン エス．エー． 抗タウ抗体及び使用方法
US10400018B2 (en) 2014-02-14 2019-09-03 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
US11124552B2 (en) 2017-10-25 2021-09-21 Ac Immune Sa Compositions of phosphorylated tau peptides and uses thereof
EP3920966A2 (en) 2019-02-08 2021-12-15 AC Immune S.A. Method of safe administration of phosphorylated tau peptide vaccine
BR112021021213A2 (pt) 2019-04-24 2021-12-21 Ac Immune Sa Administração heteróloga de vacinas de tau

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0544942A1 (en) * 1991-12-06 1993-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel tools for the diagnosis and treatment of Alzheimer disease
WO1994019692A1 (en) * 1993-02-18 1994-09-01 The General Hospital Corporation Alzheimer's disease therapeutics
US20020086009A1 (en) * 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
US6495376B1 (en) * 1999-02-18 2002-12-17 Beth Israel Deaconess Medical Center Methods and compositions for regulating protein-protein interactions

Also Published As

Publication number Publication date
JP2004503747A (ja) 2004-02-05
WO2002004949A2 (en) 2002-01-17
US20050221391A1 (en) 2005-10-06
CA2415919A1 (en) 2002-01-17
WO2002004949A3 (en) 2002-10-03
AU2001273361A1 (en) 2002-01-21
EP1301531A2 (en) 2003-04-16

Similar Documents

Publication Publication Date Title
MXPA03000316A (es) Reactivos y metodos para la identificacion de agentes de enlace.
AU8506601A (en) Binding polypeptides for b lymphocyte stimulator protein (blys)
HUP0200400A2 (hu) Fehérjék izolálása és elemzése
DE60041839D1 (de) Auto-Antikörper gegen Annexin-Proteine als Marker für Lungenkrebs
DE69833014D1 (de) Menschliche toll homologen
ATE230487T1 (de) Verfahren zur frühen diagnose von carcinomen
HK1110936A1 (en) Method for detecting misfolded proteins and prions
ATE311443T1 (de) Methoden zur durchforstung (screenen) von proteinen
FR2816410B1 (fr) Necessaire de detection de la proteine esm-1 et procede de detection mettant en oeuvre ledit necessaire
WO2000012703A3 (en) Protein transport-associated molecules
WO2000035950A3 (en) Reagents and methods useful for detecting diseases of the breast
WO2001020004A3 (en) Protein phosphatase and kinase proteins
WO2005019831B1 (en) Methods for reducing complexity of a sample using small epitope antibodies
MXPA01008605A (es) Proteina de enlace del antigeno goodpasture.
DE60218848D1 (de) Verfahren zur trennung und/oder zum nachweis und/oder zur identifizierung und/oder zur quantifizierung von prionproteinen
ATE520031T1 (de) Ibc-1 (invasive breast cancer-1), ein bei brustkrebs amplifiziertes mutmassliches onkogen
WO2003103474A3 (en) DIAGNOSTIC MARKERS FOR NERVOUS SYSTEM DISORDERS
EP1592801A4 (en) TANDEM ANALYSIS OF NON-COVALENT ENTRAINED EFFECTORS FOR MODULATORY CARTOGRAPHY OF PROTEIN SITE ACTIVITIES
WO2004110243A3 (en) COMPOSITIONS AND METHODS FOR ENHANCING THE IDENTIFICATION OF PRION PROTEIN PRPsc
WO2004074446A3 (en) Parkin interacting polypeptides and methods of use
WO2004019880A3 (en) Aw755252-interacting proteins and use thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal